UPDATE Oct. 4: A spokesperson for the FDA confirmed in a Friday email to The Christian Post that the agency figures reported in this article are accurate. The spokesperson, however, clarified that “regarding deaths specifically, these are reports with the ‘serious’ outcome of death, not the reported adverse event term ‘death.’”

Per relevant legal code, the spokesperson added, “The regulatory definition of ‘serious’ is any adverse drug experience occurring at any dose that results in any of the following outcomes: death, a life-threatening adverse drug experience, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity, or a congenital anomaly/birth defect, and other serious important medical events.”

The FDA further explained that if a search is performed on the Adverse Event Reporting System for Lupron with the adverse event term of “death,” it results in approximately 1,200 reports. When a search is performed in FAERS for Lupron reports coded with a regulatory outcome of death, it results in approximately 6,000 reports.

“The adverse event term and regulatory outcome are different concepts, but it is expected that all reports with an adverse event term of death are captured among those reports coded with the serious regulatory outcome of death,” the spokesperson said.

Original report:

Parents of kids with gender dysphoria not warned about dangers of hormone blockers

A drug used to block puberty in children with gender dysphoria is responsible for the death of over 6,300 people, according to the Food & Drug Administration (FDA).

The Christian Post reports Leuprolide Acetate (Lupron) “is being prescribed off-label for use in children who have been diagnosed with gender dysphoria despite the lack of formal FDA approval for that purpose.”

“The drug is clinically approved for treatment of precocious puberty, a condition where children start their pubertal processes at an abnormally early age and the blocker is administered for a short time until the proper age,” the outlet continues.

Citing FDA data, the article reads, “Between 2012 and June 30 of this year, the FDA documented over 40,764 adverse reactions suffered by patients who took Leuprolide Acetate (Lupron), which is used as a hormone blocker. More than 25,500 reactions logged from 2014-2019 were considered ‘serious,’ including 6,370 deaths.”

A California-based endocrinologist named Michael Laidlaw has been exposing the controversial tactic of prescribing testosterone to girls as young as 8 who suffer from gender dysphoria.

Laidlaw argues, “Gender dysphoria is not an endocrine condition, but is a psychological one and should, therefore, be treated with proper psychological care.”

However, when puberty blockers are given to children, an endocrine condition is created.

This dangerous practice is becoming increasingly lucrative for Big Pharma company AbbVie, with Lupron sales in the United States hitting $669 million in 2017.

By Kelen McBreen